J. Llovet

Hepatology · 2001–2023

A researcher in the Science corpus: 47 papers; trusts 19 researchers and is trusted by 41 researchers here, as inferred from the citation graph.

Subfields

• Hepatology — 565 citations into it; #3 of 151 by trust here, #1 by citations
• Oncology — 351 citations into it; #1,069 of 1,698 by trust here, #516 by citations
• Epidemiology — 325 citations into it; #956 of 2,148 by trust here, #90 by citations
• Surgery — 182 citations into it; #978 of 1,106 by trust here, #74 by citations
• Pathology and Forensic Medicine — 90 citations into it; #35 of 414 by trust here, #44 by citations
• Radiology, Nuclear Medicine and Imaging — 22 citations into it; #2,905 of 3,265 by trust here, #1,699 by citations

Whom J. Llovet trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Jordi Bruix1 , 2
2. Riccardo Lencioni
3. C. Lo
4. M. Sherman
5. A. Cheng
6. F. Bray
7. P. Farazi
8. J. Ferlay
9. A. Villanueva
10. R. Finn

Who trusts J. Llovet overall

1. Riccardo Lencioni
2. Jordi Bruix1 , 2
3. Alejandro Forner1 , 2
4. Amit G. Singal
5. M. Sherman
6. Peter R. Galle
7. L. Kulik
8. R. Salem
9. María E. Reig1 , 2
10. Michel Ducreux

Papers from J. Llovet's perspective

Ordered by how strongly the researchers J. Llovet trusts endorse each paper. Same corpus, a different order for every researcher.

1. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
3. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. (Gastroenterology)
4. Novel advancements in the management of hepatocellular carcinoma in 2008. (Journal of Hepatology)
5. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling (Hepatology)
6. Portal Vein Embolization Before Right Hepatectomy: Prospective Clinical Trial (Annals of Surgery)
7. The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients (Hepatology)
8. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. (American Journal of Epidemiology)
9. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival (Hepatology)
10. INCIDENCE OF HEPATOCELLULAR CARCINOMA AND ASSOCIATED RISK FACTORS IN HEPATITIS C-RELATED ADVANCED LIVER DISEASE (Gastroenterology)

Their papers

• Pivotal role of mTOR signaling in hepatocellular carcinoma. (2008) — 725 citations
• Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma (2008) — 1,244 citations
• Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling (2008) — 1,383 citations
• Focal Gains of Vascular Endothelial Growth Factor A and Molecular Classification of Hepatocellular Carcinoma (2008) — 647 citations
• AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023) — 1,275 citations
• Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy (2023) — 771 citations
• Immunotherapies for hepatocellular carcinoma (2021) — 1,513 citations
• NASH limits anti-tumour surveillance in immunotherapy-treated HCC (2021) — 1,066 citations
• Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma (2021) — 840 citations
• Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020) — 879 citations
• β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma (2019) — 600 citations
• Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) — 1,383 citations
• Molecular therapies and precision medicine for hepatocellular carcinoma (2018) — 1,675 citations
• EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018) — 8,228 citations
• Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features (2017) — 804 citations
• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017) — 3,215 citations
• Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis (2016) — 1,028 citations
• Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. (2016) — 660 citations
• Hepatocellular carcinoma (2016) — 1,645 citations
• Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. (2015) — 937 citations